Hudson Therapeutics, the U.S. Subsidiary of Shaperon, Announces Initiation of Phase 2b Part 2 Clinical Trial for NuGel
Next-Generation Atopic Dermatitis Treatment Moves Forward with Global Development and Licensing Opportunities…
Tag: shaperon,